Co-Authors
This is a "connection" page, showing publications co-authored by Fatima Laher and Lynn Morris.
Connection Strength
0,548
-
Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines. PLoS Med. 2020 02; 17(2):e1003038.
Score: 0,178
-
Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. AIDS. 2010 Jul 17; 24(11):1679-87.
Score: 0,091
-
Pharmacokinetic serum concentrations of VRC01 correlate with prevention of HIV-1 acquisition. EBioMedicine. 2023 Jul; 93:104590.
Score: 0,056
-
Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition. N Engl J Med. 2021 03 18; 384(11):1003-1014.
Score: 0,048
-
Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials. PLoS Med. 2020 05; 17(5):e1003117.
Score: 0,045
-
Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa. Sci Transl Med. 2019 09 18; 11(510).
Score: 0,043
-
Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial. Lancet HIV. 2018 07; 5(7):e366-e378.
Score: 0,040
-
Adherence to drug-refill is a useful early warning indicator of virologic and immunologic failure among HIV patients on first-line ART in South Africa. PLoS One. 2011 Mar 09; 6(3):e17518.
Score: 0,024
-
Drug resistance patterns and virus re-suppression among HIV-1 subtype C infected patients receiving non-nucleoside reverse transcriptase inhibitors in South Africa. J AIDS Clin Res. 2011 Feb 18; 2(117).
Score: 0,024